Coherus Biosciences (CHRS) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a hold rating to a buy rating in a report issued on Saturday morning, ValuEngine reports.

A number of other equities research analysts have also recently commented on CHRS. BidaskClub raised Coherus Biosciences from a sell rating to a hold rating in a report on Thursday, January 31st. Zacks Investment Research lowered Coherus Biosciences from a hold rating to a sell rating in a research report on Thursday, March 7th. Credit Suisse Group set a $25.00 price objective on Coherus Biosciences and gave the company a buy rating in a research report on Thursday, March 7th. Maxim Group restated a buy rating and set a $25.00 price objective on shares of Coherus Biosciences in a research report on Monday, April 8th. Finally, Robert W. Baird set a $28.00 price objective on Coherus Biosciences and gave the company a buy rating in a research report on Wednesday, April 10th. Eight research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus price target of $28.33.

NASDAQ:CHRS traded up $0.99 on Friday, reaching $18.55. 1,053,814 shares of the company’s stock traded hands, compared to its average volume of 771,086. The company has a quick ratio of 2.49, a current ratio of 3.84 and a debt-to-equity ratio of 8.29. The stock has a market cap of $1.29 billion, a PE ratio of -5.76 and a beta of 3.64. Coherus Biosciences has a 12 month low of $8.32 and a 12 month high of $20.66.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.82) by ($0.10). Sell-side analysts anticipate that Coherus Biosciences will post -0.8 earnings per share for the current fiscal year.

In other news, CFO Jean-Frederic Viret sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $14.92, for a total transaction of $44,760.00. Following the completion of the transaction, the chief financial officer now owns 13,185 shares in the company, valued at $196,720.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 18.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Coherus Biosciences in the first quarter worth about $108,000. Legal & General Group Plc grew its position in Coherus Biosciences by 12.3% in the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 998 shares in the last quarter. Roman Butler Fullerton & Co. purchased a new position in Coherus Biosciences in the fourth quarter worth about $122,000. Principal Financial Group Inc. purchased a new position in Coherus Biosciences in the first quarter worth about $145,000. Finally, BNP Paribas Arbitrage SA grew its position in Coherus Biosciences by 107,870.0% in the first quarter. BNP Paribas Arbitrage SA now owns 10,797 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 10,787 shares in the last quarter. Institutional investors own 96.20% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

See Also: Book Value Per Share in Stock Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.